Aditxt, Inc. announced that On December 24, 2021, Lauren Chung notified the Company that effective December 31, 2021, she is resigning from
the Company's Board of Directors. Ms. Chung's resignation was not the result of any disagreement with the
Company relating to its operations, policies or practices. On December 26, 2021, Laura Anthony notified the Company that effective December 31, 2021, she is resigning from the Company's Board of Directors. Ms. Anthony served as a member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. Ms. Anthony's resignation was not the result of any disagreement with the Company relating to its operations, policies or practices.
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
ADITXT, INC. 
